Canadá - inglés - Health Canada

pfizer canada ulc - norethindrone; ethinyl estradiol - tablet - 1mg; 0.035mg - norethindrone 1mg; ethinyl estradiol 0.035mg - contraceptives

Canadá - inglés - Health Canada

pfizer canada ulc - norethindrone; ethinyl estradiol - tablet - 1mg; 0.035mg - norethindrone 1mg; ethinyl estradiol 0.035mg - contraceptives

Estados Unidos - inglés - NLM (National Library of Medicine)

kaiser foundation hospitals - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergotamine tartrate 1 mg

Estados Unidos - inglés - NLM (National Library of Medicine)

horizon pharma inc. - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - ergotamine tartrate 2 mg - ergotamine tartrate and caffeine indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergotamine tartrate and caffeine may cause fetal harm when administered to preg

Estados Unidos - inglés - NLM (National Library of Medicine)

rosedale therapeutics - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergotamine tartrate 2 mg - ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or a so-called "histaminic cephalalgia". coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergomar® sublingual tablets may cause fetal harm when administered to pregnant women. ergomar® sublingual tablets are con

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sumatriptan succinate, quantity: 140 mg - tablet - excipient ingredients: lactose; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - sumatriptan tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of sumatriptan tablets in the treatment of basilar or hemiplegic migraine.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sumatriptan succinate, quantity: 70 mg - tablet - excipient ingredients: magnesium stearate; colloidal anhydrous silica; lactose; microcrystalline cellulose; crospovidone; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400 - sumatriptan tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of sumatriptan tablets in the treatment of basilar or hemiplegic migraine.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - sumatriptan succinate, quantity: 70 mg - tablet - excipient ingredients: lactose; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400 - sumatriptan tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of sumatriptan tablets in the treatment of basilar or hemiplegic migraine.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - sumatriptan succinate, quantity: 70 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400 - for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ritonavir, quantity: 100 mg - tablet, film coated - excipient ingredients: macrogol 3350; macrogol 400; sodium stearylfumarate; titanium dioxide; calcium hydrogen phosphate; sorbitan monolaurate; copovidone; hyprolose; purified talc; polysorbate 80; hypromellose; colloidal anhydrous silica - norvir (ritonavir) is indicated for use in combination with appropriate antiretriviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks in duration ( see clinical trials).